← Leaderboards
Mark Gerelus
University Of Pennsylvania
$113,006
Attributed
$113,006
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $45.5K · FY2020–22$50K$37.5K$25K$12.5K$0
'20
'21
'22
Funding mix
By agency
NIH$113,006 · 1
By mechanism
F31$113,006 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Don-On Daniel Mak$4,975,182
- Brian James Altman$1,916,254
- Stephan A Grupp$7,570,044
- Jonathan A Epstein$30,695,974
- J. Kevin Kevin Foskett$22,784,994
Others in their field
Other Emerging Leaders on “Anaplastic Lymphoma Kinase”
- Javeed Iqbal · University Of Nebraska Medical Center$2,198,356
- Daryl Ewald Klein · Yale University$1,888,960
- Jessica Jiyeong Lin · Massachusetts General Hospital$1,690,059
- Mark M. Awad · Dana-Farber Cancer Inst$878,255
- Muhammed Murtaza · Translational Genomics Research Inst$609,103
- Carlos A. Murga-Zamalloa · University Of Michigan At Ann Arbor$319,593
Research focus
Anaplastic Lymphoma KinaseAntitumor ResponseBaseBiologicalCell DeathCell LineCell ModelCellsCell SurvivalChildhoodClinicClinical EffectClinically RelevantClinical Trials DesignCombatCombined Modality TherapyCrispr/Cas TechnologyCrizotinibCytoplasmDiagnosisDoseDrug DevelopmentDrug TargetingAlk Gene
Grant awards (3)
Elucidating the therapeutic tractability and functional role of SHP2 in ALK-driven high-risk neuroblastoma$34,101
F31 · FY2022 · CA · contact PI
Elucidating the therapeutic tractability and functional role of SHP2 in ALK-driven high-risk neuroblastoma$33,385
F31 · FY2021 · CA · contact PI
Elucidating the therapeutic tractability and functional role of SHP2 in ALK-driven high-risk neuroblastoma$45,520
F31 · FY2020 · CA · contact PI